INmuneBIO Ph2 XPRO1595-AD-02

Back to Drug Development Trials
Drug Development Trials

About the trial

An Open-Label Extension of Xpro1595 in patients with Alzheimer’s Disease (AD) or Mild Cognitive Impairment (MCI) due to AD that have completed a Phase 2 study with Xpro1595.